Submit Search
Upload
Screening cáncer próstata, nejm, marzo 2017
•
1 like
•
328 views
marcela maria morinigo kober
Follow
Hacerlo versus no hacerlo... Ese es el dilema...
Read less
Read more
Health & Medicine
Report
Share
Report
Share
1 of 5
Download now
Download to read offline
Recommended
5.16.11.aggressive vs. indolent prostate tumors
5.16.11.aggressive vs. indolent prostate tumors
Максим Зеленский
tom3
tom3
Alexandra Resney
Screening for Prostate Cancer NEJM cases 2012
Screening for Prostate Cancer NEJM cases 2012
Aieme Uam
PIVOT
PIVOT
Institute for the Study of Urologic Diseases
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
Dr Ali MUJTABA
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
summer elmorshidy
Prostate Cancer Resources
Prostate Cancer Resources
BrightStar Care
Prostate Cancer Testing and Screening
Prostate Cancer Testing and Screening
Catherine Holborn
Recommended
5.16.11.aggressive vs. indolent prostate tumors
5.16.11.aggressive vs. indolent prostate tumors
Максим Зеленский
tom3
tom3
Alexandra Resney
Screening for Prostate Cancer NEJM cases 2012
Screening for Prostate Cancer NEJM cases 2012
Aieme Uam
PIVOT
PIVOT
Institute for the Study of Urologic Diseases
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
EAU - Guidelines on Prostate Cancer dr. ali mujtaba
Dr Ali MUJTABA
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
summer elmorshidy
Prostate Cancer Resources
Prostate Cancer Resources
BrightStar Care
Prostate Cancer Testing and Screening
Prostate Cancer Testing and Screening
Catherine Holborn
Prostate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, Haematuria
Marc Laniado
Psa guideline exercise
Psa guideline exercise
John Voss
Assessment of Incidence and Prevalence of Prostate Cancer in Middle Aged Male...
Assessment of Incidence and Prevalence of Prostate Cancer in Middle Aged Male...
BRNSS Publication Hub
What’s new in prostate cancer part 1, 2021
What’s new in prostate cancer part 1, 2021
Robert J Miller MD
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista Lemaire
Niela Valdez
Active Surveillance for Prostate Cancer
Active Surveillance for Prostate Cancer
Europa Uomo EPAD
Prostate cancer Organ Confined by Dr. Ali Mujtaba
Prostate cancer Organ Confined by Dr. Ali Mujtaba
Dr Ali MUJTABA
Multidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer Unit
Europa Uomo EPAD
Prostate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queries
Marc Laniado
Prolaris presentation in Greece 2014
Prolaris presentation in Greece 2014
Marc Laniado
PSA test accuracy
PSA test accuracy
Gaetan Lion
Prostate specific antigen
Prostate specific antigen
Priyanka Malekar
Pros and cons of prostate cancer screening by mungai ngugi
Pros and cons of prostate cancer screening by mungai ngugi
Kesho Conference
Prostate Cancer Treatment - Active Surveillance
Prostate Cancer Treatment - Active Surveillance
Lindsay Rosenwald
Psa
Psa
janmacmann
Prostate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminar
HarshaR35
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
European School of Oncology
Prostate Cancer And Screening
Prostate Cancer And Screening
Summit Health
Prolaris improving the prognosis of prostate cancer
Prolaris improving the prognosis of prostate cancer
Marc Laniado
Prostate Cancer Screening
Prostate Cancer Screening
Peninsula Coastal Region of Sutter Health
Fisiología de la visión
Fisiología de la visión
yumaath
Curs 5 artritele
Curs 5 artritele
claudiu horga
More Related Content
What's hot
Prostate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, Haematuria
Marc Laniado
Psa guideline exercise
Psa guideline exercise
John Voss
Assessment of Incidence and Prevalence of Prostate Cancer in Middle Aged Male...
Assessment of Incidence and Prevalence of Prostate Cancer in Middle Aged Male...
BRNSS Publication Hub
What’s new in prostate cancer part 1, 2021
What’s new in prostate cancer part 1, 2021
Robert J Miller MD
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista Lemaire
Niela Valdez
Active Surveillance for Prostate Cancer
Active Surveillance for Prostate Cancer
Europa Uomo EPAD
Prostate cancer Organ Confined by Dr. Ali Mujtaba
Prostate cancer Organ Confined by Dr. Ali Mujtaba
Dr Ali MUJTABA
Multidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer Unit
Europa Uomo EPAD
Prostate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queries
Marc Laniado
Prolaris presentation in Greece 2014
Prolaris presentation in Greece 2014
Marc Laniado
PSA test accuracy
PSA test accuracy
Gaetan Lion
Prostate specific antigen
Prostate specific antigen
Priyanka Malekar
Pros and cons of prostate cancer screening by mungai ngugi
Pros and cons of prostate cancer screening by mungai ngugi
Kesho Conference
Prostate Cancer Treatment - Active Surveillance
Prostate Cancer Treatment - Active Surveillance
Lindsay Rosenwald
Psa
Psa
janmacmann
Prostate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminar
HarshaR35
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
European School of Oncology
Prostate Cancer And Screening
Prostate Cancer And Screening
Summit Health
Prolaris improving the prognosis of prostate cancer
Prolaris improving the prognosis of prostate cancer
Marc Laniado
Prostate Cancer Screening
Prostate Cancer Screening
Peninsula Coastal Region of Sutter Health
What's hot
(20)
Prostate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, Haematuria
Psa guideline exercise
Psa guideline exercise
Assessment of Incidence and Prevalence of Prostate Cancer in Middle Aged Male...
Assessment of Incidence and Prevalence of Prostate Cancer in Middle Aged Male...
What’s new in prostate cancer part 1, 2021
What’s new in prostate cancer part 1, 2021
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista Lemaire
Active Surveillance for Prostate Cancer
Active Surveillance for Prostate Cancer
Prostate cancer Organ Confined by Dr. Ali Mujtaba
Prostate cancer Organ Confined by Dr. Ali Mujtaba
Multidisciplinarity and the Prostate Cancer Unit
Multidisciplinarity and the Prostate Cancer Unit
Prostate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queries
Prolaris presentation in Greece 2014
Prolaris presentation in Greece 2014
PSA test accuracy
PSA test accuracy
Prostate specific antigen
Prostate specific antigen
Pros and cons of prostate cancer screening by mungai ngugi
Pros and cons of prostate cancer screening by mungai ngugi
Prostate Cancer Treatment - Active Surveillance
Prostate Cancer Treatment - Active Surveillance
Psa
Psa
Prostate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminar
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
Prostate Cancer And Screening
Prostate Cancer And Screening
Prolaris improving the prognosis of prostate cancer
Prolaris improving the prognosis of prostate cancer
Prostate Cancer Screening
Prostate Cancer Screening
Viewers also liked
Fisiología de la visión
Fisiología de la visión
yumaath
Curs 5 artritele
Curs 5 artritele
claudiu horga
Pecha kucha rev 20170331
Pecha kucha rev 20170331
Jesús Vela Comino
Funciones
Funciones
noelcespedes
Plgia social
Plgia social
26844369
Terminos de referencia trabajo final
Terminos de referencia trabajo final
Lenin Monsalve
Atelier creativi eas
Atelier creativi eas
Laura Antichi
Proceso de Atencion de Enfermeria a niños con Alteraciones Urinarias y Genito...
Proceso de Atencion de Enfermeria a niños con Alteraciones Urinarias y Genito...
Gisela Salas Gonzalez
Funciones superiores
Funciones superiores
yumaath
Plano quebra cabeça humano
Plano quebra cabeça humano
PIBIDSolondeLucena
Sociedade da Informação
Sociedade da Informação
Professor Juliano Domingues da Silva - Universidade Católica de Pernambuco (Unicap)
Caso 1 interbank Itil Maestria
Caso 1 interbank Itil Maestria
Roberto Carlos Moncada Lopez
ISP summit - Toronto 2016
ISP summit - Toronto 2016
Massimo Candela
Teoría de la identidad social
Teoría de la identidad social
Roquism
Taller publicidad redes sociales 2017
Taller publicidad redes sociales 2017
Rekrea
02 una herencia incorruptible
02 una herencia incorruptible
chucho1943
La raíz de la política venezolana
La raíz de la política venezolana
Germaileth Gonzalez
Libert y resume
Libert y resume
Libert Youssa-Tientcheu
Accidentes de trabajo causas, efectos y prevención
Accidentes de trabajo causas, efectos y prevención
Jose Miguel Barreto Jimenez
Arquitectura Barroca
Arquitectura Barroca
Maria Pascale
Viewers also liked
(20)
Fisiología de la visión
Fisiología de la visión
Curs 5 artritele
Curs 5 artritele
Pecha kucha rev 20170331
Pecha kucha rev 20170331
Funciones
Funciones
Plgia social
Plgia social
Terminos de referencia trabajo final
Terminos de referencia trabajo final
Atelier creativi eas
Atelier creativi eas
Proceso de Atencion de Enfermeria a niños con Alteraciones Urinarias y Genito...
Proceso de Atencion de Enfermeria a niños con Alteraciones Urinarias y Genito...
Funciones superiores
Funciones superiores
Plano quebra cabeça humano
Plano quebra cabeça humano
Sociedade da Informação
Sociedade da Informação
Caso 1 interbank Itil Maestria
Caso 1 interbank Itil Maestria
ISP summit - Toronto 2016
ISP summit - Toronto 2016
Teoría de la identidad social
Teoría de la identidad social
Taller publicidad redes sociales 2017
Taller publicidad redes sociales 2017
02 una herencia incorruptible
02 una herencia incorruptible
La raíz de la política venezolana
La raíz de la política venezolana
Libert y resume
Libert y resume
Accidentes de trabajo causas, efectos y prevención
Accidentes de trabajo causas, efectos y prevención
Arquitectura Barroca
Arquitectura Barroca
Similar to Screening cáncer próstata, nejm, marzo 2017
New study confirms psa screening saves lives
New study confirms psa screening saves lives
Rebecca Sage
5.16.11.aggressive vs. indolent prostate tumors
5.16.11.aggressive vs. indolent prostate tumors
Максим Зеленский
11 aug 12 treating prostate cancer
11 aug 12 treating prostate cancer
wonmedcen
Medco CE - Prostate Cancer
Medco CE - Prostate Cancer
Crea Healthcare Partnering, Inc.
tom
tom
Alexandra Resney
5.16.11 biomarkers and genetic tests
5.16.11 biomarkers and genetic tests
Максим Зеленский
5.16.11 biomarkers and genetic tests
5.16.11 biomarkers and genetic tests
Максим Зеленский
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
RonitEnterprises
Screening for carcinoma prostate
Screening for carcinoma prostate
Prakash Hs
pca screening.pdf
pca screening.pdf
ssusere131b1
Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Bhargav Kiran
Ca prostate presentation1
Ca prostate presentation1
Praveen Ganji
tom2
tom2
Alexandra Resney
Breast Cancer Screening
Breast Cancer Screening
Asha Reddy
article-le-pomit
article-le-pomit
Bart van Bergen
Screening for prostate cancer 2018
Screening for prostate cancer 2018
Robert J Miller MD
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
croysierkathey
An Investigation of the Knowledge and Opinions of British Men Regarding Pros...
An Investigation of the Knowledge and Opinions of British Men Regarding Pros...
Jedrik Martinez
Cmaj.140703.full
Cmaj.140703.full
Inaiara Bragante
Number of Pages 4 (Double Spaced)Number of sources 8Writi.docx
Number of Pages 4 (Double Spaced)Number of sources 8Writi.docx
cherishwinsland
Similar to Screening cáncer próstata, nejm, marzo 2017
(20)
New study confirms psa screening saves lives
New study confirms psa screening saves lives
5.16.11.aggressive vs. indolent prostate tumors
5.16.11.aggressive vs. indolent prostate tumors
11 aug 12 treating prostate cancer
11 aug 12 treating prostate cancer
Medco CE - Prostate Cancer
Medco CE - Prostate Cancer
tom
tom
5.16.11 biomarkers and genetic tests
5.16.11 biomarkers and genetic tests
5.16.11 biomarkers and genetic tests
5.16.11 biomarkers and genetic tests
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Screening for carcinoma prostate
Screening for carcinoma prostate
pca screening.pdf
pca screening.pdf
Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Ca prostate presentation1
Ca prostate presentation1
tom2
tom2
Breast Cancer Screening
Breast Cancer Screening
article-le-pomit
article-le-pomit
Screening for prostate cancer 2018
Screening for prostate cancer 2018
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
An Investigation of the Knowledge and Opinions of British Men Regarding Pros...
An Investigation of the Knowledge and Opinions of British Men Regarding Pros...
Cmaj.140703.full
Cmaj.140703.full
Number of Pages 4 (Double Spaced)Number of sources 8Writi.docx
Number of Pages 4 (Double Spaced)Number of sources 8Writi.docx
More from marcela maria morinigo kober
Metastatic prostate cancer, nejm 2018
Metastatic prostate cancer, nejm 2018
marcela maria morinigo kober
2018 integrative-tx-slides
2018 integrative-tx-slides
marcela maria morinigo kober
To fight burnout, organize
To fight burnout, organize
marcela maria morinigo kober
Outpatient management of fever and neutropenia in adults treated for malignan...
Outpatient management of fever and neutropenia in adults treated for malignan...
marcela maria morinigo kober
Leadership development in medicine, nejm 2018
Leadership development in medicine, nejm 2018
marcela maria morinigo kober
Outpatient talc administration by indwelling pleural catheter for malignant e...
Outpatient talc administration by indwelling pleural catheter for malignant e...
marcela maria morinigo kober
HIV associated cancers and related diseases, NEJM 2018
HIV associated cancers and related diseases, NEJM 2018
marcela maria morinigo kober
Revisión derrame pleural, NEJM 2018
Revisión derrame pleural, NEJM 2018
marcela maria morinigo kober
Larotrectinib, fase 1 2, nejm febrero 2018
Larotrectinib, fase 1 2, nejm febrero 2018
marcela maria morinigo kober
Educating undergraduate medical students about oncology. a literature review,...
Educating undergraduate medical students about oncology. a literature review,...
marcela maria morinigo kober
Intervenciones para problemas sexuales en pacientes con cáncer, jco 2018
Intervenciones para problemas sexuales en pacientes con cáncer, jco 2018
marcela maria morinigo kober
Alcohol factor de riesgo para Cáncer, Journal of Clinical Oncology, 2017
Alcohol factor de riesgo para Cáncer, Journal of Clinical Oncology, 2017
marcela maria morinigo kober
Cáncer de cérvix y embarazo
Cáncer de cérvix y embarazo
marcela maria morinigo kober
Biopsia de ganglio centinela (técnica combinada) en cáncer de mama
Biopsia de ganglio centinela (técnica combinada) en cáncer de mama
marcela maria morinigo kober
Guia para entender el cáncer de mama
Guia para entender el cáncer de mama
marcela maria morinigo kober
Tumor Germinal asociado a HIV y Patologías Oportunistas
Tumor Germinal asociado a HIV y Patologías Oportunistas
marcela maria morinigo kober
Informe Descriptivo Registro Institucional de Tumores
Informe Descriptivo Registro Institucional de Tumores
marcela maria morinigo kober
Cirugía Robótica Cáncer de Cérvix
Cirugía Robótica Cáncer de Cérvix
marcela maria morinigo kober
Analisis monoinstitucional de pacientes con cancer cuello uterino tratadas co...
Analisis monoinstitucional de pacientes con cancer cuello uterino tratadas co...
marcela maria morinigo kober
Vacuna hpv y embarazo, nejm marzo 2017
Vacuna hpv y embarazo, nejm marzo 2017
marcela maria morinigo kober
More from marcela maria morinigo kober
(20)
Metastatic prostate cancer, nejm 2018
Metastatic prostate cancer, nejm 2018
2018 integrative-tx-slides
2018 integrative-tx-slides
To fight burnout, organize
To fight burnout, organize
Outpatient management of fever and neutropenia in adults treated for malignan...
Outpatient management of fever and neutropenia in adults treated for malignan...
Leadership development in medicine, nejm 2018
Leadership development in medicine, nejm 2018
Outpatient talc administration by indwelling pleural catheter for malignant e...
Outpatient talc administration by indwelling pleural catheter for malignant e...
HIV associated cancers and related diseases, NEJM 2018
HIV associated cancers and related diseases, NEJM 2018
Revisión derrame pleural, NEJM 2018
Revisión derrame pleural, NEJM 2018
Larotrectinib, fase 1 2, nejm febrero 2018
Larotrectinib, fase 1 2, nejm febrero 2018
Educating undergraduate medical students about oncology. a literature review,...
Educating undergraduate medical students about oncology. a literature review,...
Intervenciones para problemas sexuales en pacientes con cáncer, jco 2018
Intervenciones para problemas sexuales en pacientes con cáncer, jco 2018
Alcohol factor de riesgo para Cáncer, Journal of Clinical Oncology, 2017
Alcohol factor de riesgo para Cáncer, Journal of Clinical Oncology, 2017
Cáncer de cérvix y embarazo
Cáncer de cérvix y embarazo
Biopsia de ganglio centinela (técnica combinada) en cáncer de mama
Biopsia de ganglio centinela (técnica combinada) en cáncer de mama
Guia para entender el cáncer de mama
Guia para entender el cáncer de mama
Tumor Germinal asociado a HIV y Patologías Oportunistas
Tumor Germinal asociado a HIV y Patologías Oportunistas
Informe Descriptivo Registro Institucional de Tumores
Informe Descriptivo Registro Institucional de Tumores
Cirugía Robótica Cáncer de Cérvix
Cirugía Robótica Cáncer de Cérvix
Analisis monoinstitucional de pacientes con cancer cuello uterino tratadas co...
Analisis monoinstitucional de pacientes con cancer cuello uterino tratadas co...
Vacuna hpv y embarazo, nejm marzo 2017
Vacuna hpv y embarazo, nejm marzo 2017
Recently uploaded
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
narwatsonia7
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
vidya singh
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
narwatsonia7
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
parulsinha
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
Garima Khatri
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
narwatsonia7
Call Girl Number in Panvel Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Panvel Mumbai📲 9833363713 💞 Full Night Enjoy
babeytanya
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
vidya singh
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Miss joya
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Nehru place Escorts
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Miss joya
Call Girl Coimbatore Prisha☎️ 8250192130 Independent Escort Service Coimbatore
Call Girl Coimbatore Prisha☎️ 8250192130 Independent Escort Service Coimbatore
narwatsonia7
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
makika9823
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
narwatsonia7
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
nehamumbai
(Rocky) Jaipur Call Girl - 9001626015 Escorts Service 50% Off with Cash ON De...
(Rocky) Jaipur Call Girl - 9001626015 Escorts Service 50% Off with Cash ON De...
indiancallgirl4rent
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Miss joya
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
narwatsonia7
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
aditipandeya
Recently uploaded
(20)
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Call Girl Number in Panvel Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Panvel Mumbai📲 9833363713 💞 Full Night Enjoy
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girls Service Pune Vaishnavi 9907093804 Short 1500 Night 6000 Best call ...
Call Girl Coimbatore Prisha☎️ 8250192130 Independent Escort Service Coimbatore
Call Girl Coimbatore Prisha☎️ 8250192130 Independent Escort Service Coimbatore
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Kesar Bagh Call Girl Price 9548273370 , Lucknow Call Girls Service
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Majestic 📞 9907093804 High Profile Service 100% Safe
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
(Rocky) Jaipur Call Girl - 9001626015 Escorts Service 50% Off with Cash ON De...
(Rocky) Jaipur Call Girl - 9001626015 Escorts Service 50% Off with Cash ON De...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
Screening cáncer próstata, nejm, marzo 2017
1.
S ounding B
oa r d The new engl and jour nal of medicine n engl j med 376;13 nejm.org March 30, 2017 1285 Prostate Cancer Screening — A Perspective on the Current State of the Evidence Paul F. Pinsky, Ph.D., Philip C. Prorok, Ph.D., and Barnett S. Kramer, M.D., M.P.H. After a quarter century of extensive screening for prostate cancer with prostate-specific antigen (PSA) in the United States, and after the comple- tion of two major trials examining the effects of such screening, the medical community is still divided with regard to its effectiveness and its benefits-to-harms ratio. Here, we review the cur- rent status of PSA screening and examine emerg- ing trends. In 2012, after publication of the findings from the major randomized trials of PSA-based screening for prostate cancer — the European Randomized Study of Screening for Prostate Can- cer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) — the U.S. Preventive Services Task Force (USPSTF) recommended against PSA-based screening for prostate cancer (a recommendation that is cur- rently undergoing routine review and updating).1 The 2012 statement applied to men in the gen- eral U.S. population (excluding specific high-risk groups, such as men with known BRCA muta- tions). Over the next several years, other organi- zations and professional societies in North Amer- ica issued guidelines either recommending against PSA-based screening in average-risk men or rec- ommending some form of shared decision mak- ing about screening2-7 (Table 1). With respect to shared decision making, for example, the Amer- ican College of Physicians recommended dis- cussing the benefits and harms of screening and ordering screening only when the patient ex- presses a clear preference for it. The above entities cited as the benefits of screening a reduction in prostate-specific mor- tality of approximately 1 death per 1000 men screened (the USPSTF cited a range of 0 to 1 per 1000). This rate comes from the ERSPC; specifi- cally, a difference in prostate cancer–specific mortality of 1.3 deaths per 1000 men over 13 years of follow-up and a mean of approximately two PSA screens among men in the screening group.8 In contrast, the PLCO did not show a reduction in prostate cancer–specific mortality; in a recent update, the risk ratio was 1.04 for the screened group versus the control group after a Organization Recommendation Year U.S. Preventive Services Task Force1 Recommend against routine screening at any age 2012 Canadian Task Force on Preventive Health Care2 Recommend against screening at any age 2014 American College of Preventive Medicine3 Recommend against screening at any age 2016 American Academy of Family Physicians4 Recommend against screening at any age 2012 American Urological Association5 Implement shared decision making for men 55 to 69 yr of age and proceed on the basis of men’s values and preferences; recom- mend against screening for other ages 2013 American College of Physicians6 Discuss benefits and harms for men 50 to 69 yr of age and order screening only if clear preference is expressed for screening; recommend against screening for other ages 2015 National Comprehensive Cancer Network7 Offer screening after a discussion of risks and benefits for men 45 to 75 yr of age; screening for men older than 75 yr should be done cautiously and only in very healthy men 2016 Table 1. Recommendations on Prostate-Specific Antigen (PSA)–Based Screening for Prostate Cancer. The New England Journal of Medicine Downloaded from nejm.org on March 29, 2017. For personal use only. No other uses without permission. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
2.
The new engl
and jour nal of medicine n engl j med 376;13 nejm.org March 30, 20171286 median of 15 years of follow-up.9,10 The extent to which the PLCO findings should be taken as evidence against the efficacy of PSA screening and how much its results should be “weighted” relative to those from ERSPC are questions that have been widely debated. Purely on the basis of the relative number of prostate cancer deaths, the PLCO would have roughly a one third weight (to two thirds for ERSPC), under the assumption that the trials were of similar quality (the 2012 USPSTF analysis rated both as “fair” quality). The primary issue arguing for the PLCO weight to be substantially downgraded is that of control group “contamination” — that is, the use of PSA testing in men in the control group. Estimates from the PLCO show that during the course of the trial, including the post-screening phase, ap- proximately 85% of men in the control group had undergone a PSA test at least once.10-12 Recently, a misconception has spread that in the PLCO, the control group had more screening than the intervention group. This has now been clearly demonstrated to be untrue.10,13 Further, the indirect evidence is compelling — specifi- cally, a persistently higher incidence of prostate cancer in the screened group than in the control group, of 11% overall and 27% during the screening phase of the trial, indicating more and earlier screening in that group.10 In addition, there are various metrics of intensity of PSA screening, with men in the screened group un- dergoing, during the screening phase, a mean of approximately five tests, as compared with three tests for men in the control group.11 Nonethe- less, the level of contamination probably did substantially reduce the statistical power of the trial, and thus the negative trial result must be viewed as providing only limited evidence of a lack of a benefit of PSA screening with regard to prostate cancer mortality, in concert with the USPSTF assessment of strength of evidence from the trial. An important point to note is that the widespread promotion in the United States of PSA screening before its effectiveness was proven made conducting a randomized trial problematic. This provides a cautionary lesson about embrac- ing an unproven practice while hoping for sup- port from future clinical trials. Large trials like the PLCO and ERSPC are dif- ficult undertakings, and neither trial is devoid of flaws. The PLCO data, but not the ERSPC data, have been made available to all researchers through a data-sharing website.14 These data have been used by non-PLCO researchers investigating the contamination issue in the PLCO. An issue that has been raised about the ERSPC and also noted by the USPSTF is an imbalance in treat- ments across groups, even when cancer stage is taken into account. This has been documented and investigated by ERSPC researchers, who as- sert that this imbalance was unlikely to account for the lower mortality in the screened group.15,16 Having the ERSPC data also made widely avail- able, as a recent commentary has called for, would allow outside researchers, for example, to per- form their own analyses of the potential impli- cations of treatment imbalances on the ERSPC findings.17 When all these considerations are taken into account, the estimate of approximately 1 prostate cancer death averted per 1000 men screened several times each and followed for 10 to 15 years seems a reasonable summary of the evidence. In any case, establishing whether there is any benefit associated with PSA screening is only one side of the equation. Harms associated with the treatment of prostate cancer are common, and the recommendations against screening derive from the conclusion that the harms may outweigh any likely benefits. Noted harms in- cluded false positive tests and their downstream sequelae, such as anxiety and complications of diagnostic tests, including biopsy.1-6 In this re- spect, PSA screening is similar to other cancer screening methods. What distinguishes PSA test- ing among cancer screening tests with respect to harms is the extent of overdiagnosis of indolent, nonlethal cancers combined with the frequency and severity of side effects from the standard therapies used to treat such cancers. As has been well documented, the advent of PSA screening created a pseudoepidemic of diagnoses of pros- tate cancer. The incidence rose from approximate- ly 135 (per 100,000) at the dawn of the PSA era (1987 and 1988) to a mean of 220 in the period 1991 through 1993 (a 63% increase) and contin- ued to be well above 150 through 2009.18 Data from the ERSPC show approximately 35 over diagnosed cases per 1000 men screened, which amounted to 27 additional cases per prostate cancer death averted.8 The USPSTF evidence review estimated that radical prostatectomy was associated with a 20-percentage-point increase in the risk of uri- The New England Journal of Medicine Downloaded from nejm.org on March 29, 2017. For personal use only. No other uses without permission. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
3.
Sounding Board n engl
j med 376;13 nejm.org March 30, 2017 1287 nary incontinence and a 30-percentage-point in- crease in the risk of erectile dysfunction after 1 to 10 years.19 Radiation treatment was estimated to increase the risk of erectile dysfunction by 17 per- centage points, as well as to increase the risk of bowel dysfunction.19 Active surveillance — also known as active monitoring, a strategy of moni- toring and delayed initiation of curative treat- ment — has the potential to reduce the harms of overdiagnosis while maintaining the benefits of early detection. An additional consideration in judging the benefits-to-harms tradeoff is that many of the harms are front-loaded, occurring much earlier than benefits, which are delayed by years. That raises the question of how long one must wait to realize the benefits to counterbalance the well- established harms. The recently completed ran- domized Prostate Testing for Cancer and Treat- ment (ProtecT) trial of treatment for localized prostate cancer probably provides the most rele- vant evidence from a population of men with prostate cancer detected through screening. In that trial, 1643 men who received a diagnosis of prostate cancer after a one-time PSA screen were randomly assigned to active monitoring (primar- ily PSA monitoring), radical prostatectomy, or radiation therapy.20 After a median of 10 years of follow-up, prostate cancer–specific survival was approximately 99% in all three study groups, with no significant difference between groups (although power was limited because of low event rates). Through the 10-year follow-up period, 55% of men in the active monitoring group received curative treatment. A higher rate of metastatic progression was observed in the active monitor- ing group (6%) than in the other groups (approxi- mately 3%), a difference that began to emerge within 3 to 4 years. However, that difference did not translate into a difference in prostate cancer death rates, even after 6 to 7 more years of follow- up. In addition, the definition of metastatic progression included asymptomatic disease de- fined by high PSA levels (>100 ng per milliliter) or on the basis of imaging studies alone, so the clinical significance of the metastatic disease end point is unclear. Although the ProtecT trial left some questions unanswered about the rela- tive merits of active monitoring, it did confirm a very high survival rate among men with local- ized disease even without immediate curative treatment, which suggests that any benefits of early detection are likely to be far in the future; in contrast, the harms tend to start early and persist, especially in association with immediate radical prostatectomy or radiation therapy. Pro- tecT also highlighted the fact that a substantial proportion of men undergoing active monitoring still receive treatment at some point. PSA testing rates have declined since the USPSTF guidelines were released. The most re- cent USPSTF recommendation was published in May 2012, with a draft report published in Octo- ber 2011. From 2010 to 2013, among men 50 to 59 years of age, screening rates decreased from 33.2% to 24.8%; among men 60 to 74 years of age, rates decreased from 51.2% to 43.6%.21 An- other study showed a decrease over the same period from 37.8% to 30.8% among men older than 50 years of age.22 This decrease in screening was accompanied by a decline in prostate cancer incidence. Data from the Surveillance, Epidemi- ology, and End Results Program (SEER) show a gradual decline in incidence from 2001 to 2011 of approximately 23% over the decade, followed by a precipitous 20% decrease in 1 year from 2011 to 2012 and another small decrease (6%) from 2012 to 2013.18 Therefore, these recommendations constitute a “natural experiment” that reflects population- level changes in PSA screening patterns. Because of various gaps and delays in obtaining critical data, however, as well as the extended time it takes for prostate tumors to progress, the chal- lenge is to analyze the results of this experiment in terms of the effect of these changes on pros- tate cancer mortality as quickly and accurately as possible. Just as the decline of approximately 45% in U.S. prostate cancer mortality rates from the late 1980s to the present has been analyzed for its potential relationship to the rise in PSA screening (with the findings equivocal because of likely confounding by increasingly effective sys- temic therapies), so any future trends in prostate cancer mortality (and incidence) will be analyzed for their relationship to decreasing PSA testing trends. A recent analysis of SEER data showed essen- tially no change from 2005 to 2013 in the inci- dence of distant-stage disease at diagnosis (among men 50 to 74 years of age), although changes could appear after more time has passed.23 Going forward, rates of distant-stage disease at diagno- sis could be an early indicator of changes in The New England Journal of Medicine Downloaded from nejm.org on March 29, 2017. For personal use only. No other uses without permission. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
4.
The new engl
and jour nal of medicine n engl j med 376;13 nejm.org March 30, 20171288 mortality. However, early detection through PSA screening could be resulting in the diagnosis of prostate cancer in men at a time when they have no evidence of distant disease but in whom, because of micrometastases, clinically evident distant disease will develop later, despite early detection and treatment.24 In such a scenario, screening would lower the incidence of distant- stage disease but not the occurrence rate of meta- static disease. Unfortunately, however, those data (on cumulative occurrence rates of metastatic disease) are not currently available in SEER. Prostate cancer mortality remains the most reli- able end point for which nationally representative data are available. Note there is also a several- year lag in incidence from SEER and in national mortality rates, which makes analysis of real- time trends difficult. It is tempting to use other data sources, which may be available sooner, to assess the ef- fects of reduced screening. However, the poten- tial for misinterpretation with such sources is great. With less screening, indolent cases would be expected to disproportionately decrease, since those are the ones most likely to be detected during screening. Accordingly, the proportion of prostate cancers that are advanced would be expected to increase, and therefore the mere fact of such an increase is not meaningful. That there is still no clarity about the useful- ness and desirability of routine PSA-based screen- ing after 25 years and two large trials suggests that its net benefit is unlikely to be more than marginal, whereas the harms are proven and substantial. Under the “first do no harm” prin- ciple, it seems reasonable to forgo mass screen- ing as a public health policy at this point but to continue to perform research on how to reduce the harms of PSA screening while maintaining any benefits. Some suggested modifications, in- cluding screening less frequently (than annually) and discontinuing screening for men with very low PSA values, may decrease health care costs and harms associated with false positive tests while having a minimal effect on screening ben- efits. Active monitoring may relieve some of the burdens of overtreatment, but the required peri- odic biopsies (if they are a component of the surveillance strategy), the anxiety from delaying treatment, and the high rate of eventually under- going surgical or radiation treatment — with their attendant side effects — are substantial harms that are still incurred.25 There is a critical need for strategies to reduce the burdens associ- ated with the diagnosis of indolent disease, through a combination of not diagnosing it in the first place and accurately classifying it as not needing any further follow-up or treatment, while still maintaining any mortality benefits for men with aggressive disease. Perhaps that is the most pressing research challenge going forward. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. From the Division of Cancer Prevention, National Cancer Insti- tute, National Institutes of Health, Bethesda, MD. Address re- print requests to Dr. Pinsky at the National Cancer Institute, 9609 Medical Center Dr., Rm. 5E108, Bethesda, MD, 20892, or at pp4f@nih.gov. 1. Moyer VA. Screening for prostate cancer: U.S. Preventive Ser- vices Task Force recommendation statement. Ann Intern Med 2012;157:120-34. 2. Bell N, Connor Gorber S, Shane A, et al. Recommendations on screening for prostate cancer with the prostate-specific anti- gen test. CMAJ 2014;186:1225-34. 3. Livingston CJ, Freeman RJ, Mohammad A, et al. Choosing Wisely in preventive medicine: the American College of Preven- tive Medicine’s top 5 list of recommendations. Am J Prev Med 2016;51:141-9. 4. American Academy of Family Physicians. Prostate cancer: clinical preventive service recommendation. 2012 (http://www .aafp.org/patient-care/clinical-recommendations/all/prostate -cancer.html). 5. American Urological Association. Early detection of prostate cancer: AUA guideline, 2013 (https://www.auanet.org/education/ guidelines/prostate-cancer-detection.cfm). 6. Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med 2015;162:718-25. 7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:prostate cancer early detection, version 2.2016 (https://www.nccn.org/professionals/physician_gls/ pdf/prostate_detection.pdf). 8. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. 9. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate can- cer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32. 10. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123:592-9. 11. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate com- ponent of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010;7:303-11. 12. Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med 2016;374:1795-6. 13. Pinsky P, Prorok P. More on reevaluating PSA testing rates in the PLCO trial. N Engl J Med 2016;375:1500-1. 14. Cancer Data Access System (CDAS) home page (https:// biometry.nci.nih.gov/cdas). 15. Bokhorst LP, Venderbos LD, Schröder FH, Bangma CH, Steyer- The New England Journal of Medicine Downloaded from nejm.org on March 29, 2017. For personal use only. No other uses without permission. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
5.
Sounding Board n engl
j med 376;13 nejm.org March 30, 2017 1289 berg EW, Roobol MJ. Do treatment differences between arms affect the main outcome of ERSPC Rotterdam. J Urol 2015;194: 336-42. 16. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010;126:2387-93. 17. Haines IE, Ablin RJ, Miklos GL. Screening for prostate cancer: time to put all the data on the table. BMJ 2016;353:i2574. 18. Surveillance, Epidemiology, and End Results (SEER). Cancer Statistics Review (CSR) 1975–2013 (http://seer.cancer.gov/csr/ 1975_2013/). 19. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71. 20. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415-24. 21. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416-23. 22. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recom- mendations. JAMA 2015;314:2054-61. 23. Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol 2016;2:1657-60. 24. Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate cancer — lessons in cancer dynamics. N Engl J Med 2015;373:1685-7. 25. Ruane-McAteer E, Porter S, O’Sullivan JM, Santin O, Prue G. Active surveillance for favorable-risk prostate cancer: is there a greater psychological impact than previously thought? A system- atic, mixed studies literature review. Psychooncology 2016 No- vember 15 (Epub ahead of print). DOI: 10.1056/NEJMsb1616281 Copyright © 2017 Massachusetts Medical Society. The New England Journal of Medicine Downloaded from nejm.org on March 29, 2017. For personal use only. No other uses without permission. Copyright © 2017 Massachusetts Medical Society. All rights reserved.
Download now